Inclusion Criteria:

- Subject must have read, understood, and provided written informed consent and Health
Insurance Portability and Accountability Act (HIPAA) authorization after the nature
of the study has been fully explained

- Subjects with a histologic diagnosis of unresectable stage IV melanoma (may include
mucosal melanoma)

- Tumor must be BRAF V600E mutation positive from a certified lab

- At least 4 weeks since any previous treatment (surgery, radiotherapy, or systemic
treatment)

- Women should be either: post-menopausal for at least 1 year; surgically incapable of
bearing children; or utilizing a reliable form of contraception during the study and
for at least 4 months after the final study drug infusion or ingestion; women of
childbearing potential must have a negative serum human chorionic gonadotropin
(hCG)-beta pregnancy test conducted during the screening period

- Men who may father a child must agree to the use of male contraception for the
duration of their participation in the trial and for at least 4 months after the
final temsirolimus and AZD6244 hydrogen sulfate administration

- Life expectancy >= 3 months

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Patients with brain metastases treated with surgery, radiation, or stereotactic
radiosurgery who are without evidence of progression in their brain metastases after
magnetic resonance imaging (MRI) performed at least 30 days after treatment, and are
not taking systemic steroids will be eligible

- White blood count (WBC) >= 3000 cells/mm^3

- Absolute neutrophil count (ANC) >= 1500 cells/mm^3

- Platelets >= 100,000/mm^3

- Hematocrit >= 30%

- Hemoglobin >= 9 g/dL

- Creatinine =< 2.0 mg/dL

- Aspartic transaminase (AST)/alanine transaminase (ALT) =< 2 x ULN

- Bilirubin =< 1.5 x upper limit of normal (ULN), (except subjects with Gilbert's
Syndrome who must have a total bilirubin less than 3.0 mg/dL)

- HIV negative

- Hepatitis B surface antigen (HBsAg) negative

- Anti-HCV Ab nonreactive; if reactive, subject must have a negative HCV RNA
qualitative polymerase chain reaction (PCR)

- Patients with hyperlipidemia must have adequate control with a lipid lowering agent

Exclusion Criteria:

- Any prior malignancy except for the following: adequately treated basal or squamous
cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or any
other cancer from which the subject has been disease-free for at least 5 years

- Active infection, requiring therapy, chronic active hepatitis B virus (HBV) or
hepatitis C virus (HCV); patients with HIV, who have adequate CD4 counts and who do
not require HAART therapy, are NOT excluded

- Pregnancy or nursing: due to the possibility that temsirolimus and AZD6244 hydrogen
sulfate could have a detrimental effect on the developing fetus or infant, exposure
in utero or via breast milk will not be allowed

- Any underlying medical condition which, in the opinion of the principal investigator,
will make the administration of study drug hazardous or obscure the interpretation of
adverse events

- Prior treatment with temsirolimus or AZD6244 or any prior mTOR or MEK inhibitor

- Evidence or history of significant cardiac, pulmonary, hepatic, renal, psychiatric or
gastrointestinal disease that would make the administration of temsirolimus or
AZD6244 hydrogen sulfate unsafe

- Tumor that is BRAF V600E mutation negative